The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Open accessAbstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both thalidomide and lenalidomide lack specificity for iKZF2 (Krönke et al. 2014;lu et al. 2014), as it encodes a histidine in a critical thalidomidebinding position.”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies later confirmed that the efficacy of lenalidomide in 5q-MDS was actually due to the recruitment of an unexpected neo-substrate: the kinase cK1α (CSNK1A1) which resides within the long arm of chromosome 5 (5q32) (Krönke et al. 2014) (Figure 5B, i).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“lenalidomide was shown to promote the interaction between cRBN and two members of the ikaros transcription factor family: iKZF1 and iKZF3 (gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“As such, lenalidomide can promote the interaction between cRl4 cRBN and both iKZF1 and iKZF3 resulting in their selective degradation which disrupts their role at gene promoters (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [10]
In the citing paper
“As described before, in the presence of IMiDs, CRBN E3 ligase induces the proteasomal degradation of a set neo-substrates, such as IKZF1/3[13,39], CK1α[40] and GSPT1[15].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [13]
In the citing paper
“This is further supported by the observations that PZ could selectively induce Bcl-xl but not Bcl-2 poly-ubiquitination and had no significant effect on the expression of the CRBN native substrate, glutamine synthetase (GS)36, and its neosubstrates recruited by thalidomide and its analogues including CK1α37, IKZF1, and IKZF3 (ref. 38) (Supplementary Fig. 1 f, g).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [38]
In the citing paper
“In brief, IMiDs bind the E3 ligase cereblon (CRBN), thus complementing a surface patch that subsequently recruits a variety of C2H2 zinc finger transcription factors for ubiquitination and degradation.48−51”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [50]
In the citing paper
“In brief, IMiDs were first shown to trigger CRBN-dependent proteasomal degradation of the C2H2-type zing-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).[46][47][48]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“The presence of a glutamine residue in their second zing-finger domain enables IMiD-induced degradation, 47 while the histidine residues in Helios (IKZF2) do not.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“thalidomide interacts with CRBN to form a novel surface, resulting in interactions with neosubstrates such as Ikaros (IKZF1) and Aiolos (IKZF3) and their ubiquitination and subsequent proteasomal degradation.20,21”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [20]
In the citing paper
“lenalidomide and pomalidomide induce CRBN-dependent ubiquitination and degradation of Ikaros and Aiolos, transcription factors required for the development of lymphoids and survival of multiple myeloma8–10.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [8]
In the citing paper
“Molecular glues, based on the serendipitous discovery that thalidomide and its analogues act as degrader molecules, constitute another important therapeutic class1–8.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“These drugs co-opt CRBN to target IKAROS family zinc finger 1 (IKZF1) and IKZF3 for degradation3,4,24, and are now considered as pioneering examples of molecular glues.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“CRBN appears to be emerging as a preferred E3 ligase for the first wave of TPD therapeutics in clinical trials.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“Examples here include the approved IMiD class, which relies on CRBN to degrade IKZF1/IKZF3 (refs4,5) via a molecular glue mechanism”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“thalidomide and its analogues do not inhibit the enzymatic activity of CRL4CRBN, but instead confer neomorphic activity on CRBN to mediate the selective ubiquitination and resultant proteasomal degradation of the transcription factors Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 (Aiolos) in MM cells and T cells11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“In 2013, thalidomide analogues were discovered to exert their therapeutic effects by acting as a molecular glue to recruit disease-relevant neosubstrate proteins to an E3 ubiquitin ligase, resulting in neosubstrate ubiquitination and, ultimately, proteasomal degradation11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“given that proteasome inhibitors antagonize lenalidomide-induced protein degradation11,12,55.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Most known neosubstrate proteins have been identified through proteomic analyses of different cell lineages11,15,165,166.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Ebert's gourp and Kaelin Jr's group independently demonstrated that when lenalidomide binds to CRBN, a new function of CRBN is induced, namely, to ubiquitinate and degrade Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors that are known to be responsible for the maturation of B cells [25,26].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [25]
In the citing paper
“CRBN was shown to bind the drug thalidomide in its substrate binding pocket, thereby creating a new surface to recruit other proteins for ubiquitination and degradation, such as the transcription factors Ikaros and Aiolos (IKZF1 and 3, respectively) or the kinase CK1α [70–72].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [72]
In the citing paper
“The clinical efficacy of IMiDs is driven at least in part by their capacity to induce CRBN-mediated degradation of neo-substrates: cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
In the citing paper
“cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)
Ong, S., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.427 · Cited by 917
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,006
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
Vicente, A. T. S., Moura, S. P. S. P., & Salvador, J. A. R. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01598-9 · Cited by 23
How multispecific molecules are transforming pharmacotherapy
Deshaies, R. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01262-w · Cited by 25
β-Cell Mitochondrial Dysfunction: Underlying Mechanisms and Potential Therapeutic Strategies
Darwish, R., Alcibahy, Y., Abu-Sharia, G., & Butler, A. E. (2025) · Cells · doi:10.3390/cells14231861 · Cited by 25
Lions influence the decline and habitat shift of hartebeest in a semiarid savanna
Ng’weno, C. C., Maiyo, N. J., Ali, A. H., Kibungei, A. K., & Goheen, J. R. (2017) · Journal of Mammalogy · doi:10.1093/jmammal/gyx040 · Cited by 22
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting
Buettner, R., Morales, C. J., Caserta, E., Troadec, E., Gunes, E. G., Viola, D., Khalife, J., Li, H., Keats, J. J., Christofferson, A. W., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027227 · Cited by 22
IKZF3/Aiolos Is Associated with but Not Sufficient for the Expression of IL-10 by CD4+ T Cells
Ridley, M. L., Fleskens, V., Roberts, C. A., Lalnunhlimi, S., Alnesf, A., O’Byrne, A. M., Steel, K. J. A., Povoleri, G. A. M., Sumner, J., Lavender, P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901283 · Cited by 22
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Hesterberg, R. S., Beatty, M. S., Han, Y., Fernandez, M. R., Akuffo, A. A., Goodheart, W. E., Yang, C., Chang, S., Colin, C., Alontaga, A. Y., et al. (2020) · Blood · doi:10.1182/blood.2019003257 · Cited by 22
Hu, Z., Li, H., Wang, X., Ullah, K., & Xu, G. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103996 · Cited by 23
Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Kim, Y. K., Hwang, I., Gil, J.-E., Han, B., Chiang, Y. H., Selman, W. R., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00042 · Cited by 22
Quwaider, D., Corchete, L. A., Martín‐Izquierdo, M., Hernández-Sánchez, J. M., Rojas, E. A., Cardona‐Benavides, I. J., García‐Sánz, R., Herrero, A. B., & Gutierrez, N. C. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00271-4 · Cited by 22
Targeting phosphatases: From molecule design to clinical trials
Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 23
Logic Gate Activated Lysosome Targeting DNA Nanodevice for Controlled Proteins Degradation
Shang, Y., Zhu, L., Xiao, Y., Du, S., Ji, R., Li, B., Chen, J., Deng, S., & Ren, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202311722 · Cited by 22
Differential effects of lenalidomide during plasma cell differentiation
Jourdan, M., Cren, M., Schafer, P. H., Robert, N., Duperray, C., Vincent, L., Céballos, P., Cartron, G., Rossi, J., Moreaux, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8581 · Cited by 23
Feng, Y., Su, H., Li, Y., Luo, C., Xu, H., Wang, Y., Sun, H., Wan, G., Zhou, B., & Bu, X. (2020) · Chemical Communications · doi:10.1039/c9cc08391j · Cited by 22
Sweeney, M. A., Iakova, P. A., Maneix, L., Shih, F.-Y., Cho, H. E., Sahin, E., & Catic, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-70610-0 · Cited by 21
Targeted modulation of E3 ligases using engineered ubiquitin variants
LeBlanc, N., Mallette, E., & Zhang, W. (2020) · FEBS Journal · doi:10.1111/febs.15536 · Cited by 22
Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy
Colley, A., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.001 · Cited by 20
Prodrug activation by 4,4’-bipyridine-mediated aromatic nitro reduction
Wang, Q., Song, Y., Yuan, S., Zhu, Y., Wang, W., & Chu, L. (2024) · Nature Communications · doi:10.1038/s41467-024-52604-y · Cited by 23
Domizi, P., Sarno, J., Jager, A., Merchant, M. J., Pacheco, K. Z., Yamada‐Hunter, S. A., Rotiroti, M. C., Liu, Y., Baskar, R., Reynolds, W. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58868-2 · Cited by 21
Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates
de Gialluly, M. A. S., Allen, A. R., Hayes, E. H., Zhuang, P., Goldfarb, R. B., Farrar, A. N., Federov, Y., & Adams, D. (2025) · Nature Communications · doi:10.1038/s41467-025-61818-7 · Cited by 23
Jeng, M. Y., Mumbach, M. R., Granja, J. M., Satpathy, A. T., Chang, H. Y., & Chang, A. L. S. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.09.011 · Cited by 22
Costanzo, A. D., Gaudio, N. D., Conte, L., & Altucci, L. (2020) · Cancers · doi:10.3390/cancers12071898 · Cited by 22
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Yan, Y., Shao, J., Ding, D., Pan, Y., Tran, P., Yan, W., Wang, Z., Li, H., & Huang, H. (2022) · Chemical Communications · doi:10.1039/d1cc06525d · Cited by 22
Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma
Allegra, A., Petrarca, C., Gioacchino, M. D., Casciaro, M., Musolino, C., & Gangemi, S. (2022) · Antioxidants · doi:10.3390/antiox11030455 · Cited by 21
SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
Du, L., Liu, W., Pichiorri, F., & Rosen, S. T. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00450-9 · Cited by 21
Geng, C., Chen, J., Song, T., Jung, J. H., Long, M., Song, M., Ji, T., Min, B. S., Lee, J. G., Peng, B., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.012 · Cited by 23
SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics
Sialana, F. J., Roumeliotis, T. I., Bouguenina, H., Hak, L. C. W., Wang, H., Caldwell, J., Collins, I., Chopra, R., & Choudhary, J. S. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00092 · Cited by 20
Chen, J., Jin, J., Gu, W., Zhao, Z., Hu, Y., Zhou, Y., Nagle, D. G., Xi, Q., Zhang, X., Sun, Q., et al. (2023) · Cancer Science · doi:10.1111/cas.15733 · Cited by 20
IKAROS: from chromatin organization to transcriptional elongation control
Affar, M., Bottardi, S., Quansah, N., Lemarié, M., Ramòn, A. C., Affar, E. B., & Milot, É. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01212-2 · Cited by 20
Facilitating the development of molecular glues: Opportunities from serendipity and rational design
Jiang, W., Jiang, Y., Luo, Y., Qiao, W., & Yang, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115950 · Cited by 22
Stokes, M. E., Wenzl, K., Huang, C. C., Ortiz, M., Hsu, C.-C., Maurer, M. J., Stong, N., Nakayama, Y., Wu, L., Chiu, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50830-y · Cited by 23
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2
Zhu, Y. X., Yin, H. H., Bruins, L. A., Shi, C.-X., Jedlowski, P. M., Aziz, M., Sereduk, C., Kortuem, K. M., Schmidt, J. E., Champion, M. D., et al. (2014) · Blood · doi:10.1182/blood-2014-05-577130 · Cited by 21
Browning, R. L., Byrd, W. H., Gupta, N., Jones, J. A., Mo, X. M., Hertlein, E. K., Yu, L., Muthusamy, N., & Byrd, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0291 · Cited by 21
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade
Zheng, J. J., Sha, Y., Roof, L., Foreman, O., Lazarchick, J. J., Venkata, J. K., Kozlowski, C., Gasparetto, C., Chao, N. J. A., Ebens, A. J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.003 · Cited by 21
Zhou, L., & Xu, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1317-7 · Cited by 22
Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
Stefka, A. T., Johnson, D. C., Rosebeck, S., Park, J., Nakamura, Y., & Jakubowiak, A. J. (2019) · Cancer Medicine · doi:10.1002/cam4.2695 · Cited by 21
Garcia, J. S., Bhatt, S., Fell, G. G., Sperling, A. S., Burgess, M. W., Keshishian, H., Yilma, B., Brunner, A. M., Neuberg, D. S., Carr, S. A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25692 · Cited by 21
Self-citationTargeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 21
Lin, W., Li, Y., Min, J., Liu, J., Yang, L., Lee, R. E., Jr., & Chen, T. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00507 · Cited by 21
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen
Mo, Z., Wood, S., Namiranian, S., Mizukoshi, R., Weng, S., Jang, I. S., Fontanillo, C., Baughman, J. M., Silva-Torres, A., Slade, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003431 · Cited by 20
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
Barley, K. M., He, W., Agarwal, S., Jagannath, S., & Chari, A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1151507 · Cited by 21
Potential of NK cells in multiple Myeloma therapy
Khan, A., Devarakonda, S. S., Bumma, N., Chaudhry, M., & Benson, D. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1617128 · Cited by 21
Garber, K. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02164-9 · Cited by 20
Combinatorial mapping of E3 ubiquitin ligases to their target substrates
Suiter, C. C., Calderon, D., Lee, D. S., Chiu, M., Jain, S., Chardon, F. M., Lee, C., Daza, R. M., Trapnell, C., Zheng, N., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.01.016 · Cited by 21
Discovery of an LSD1 PROTAC degrader
Hosseini, A., Qiu, X., Xiong, Y., Chiang, K. H. N., Catlett, J. L., Kaltheuner, I. H., Deng, Z., Ghosh, S., Shi, Y., & Jin, J. J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425812122 · Cited by 22
Transcription Factors and Methods for the Pharmacological Correction of Their Activity
Guryanova, S. V., Maksimova, T. V., & Мухамедовна, А. М. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136394 · Cited by 23
Maurer, C., Pflug, N., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Groß-Ophoff-Müller, C., Langerbeins, P., Fink, A., Eichhorst, B. F., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12714 · Cited by 20
Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
Piccolomo, A., Schifone, C. P., Strafella, V., Specchia, G., Musto, P., & Albano, F. (2020) · Cancers · doi:10.3390/cancers12092528 · Cited by 21
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Chen, M., Wan, Y., Li, X., Xiang, J., Chen, X., Jiang, J., Han, X., Zhong, L., Xiao, F., Liu, J., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00971-2 · Cited by 20
Self-citationJiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 22
Hartley-Brown, M. A., Mo, C. C., Nadeem, O., Midha, S., Laubach, J. P., & Richardson, P. G. G. (2024) · Cancers · doi:10.3390/cancers16061166 · Cited by 22
Trial Watch: Proteasomal inhibitors for anticancer therapy
Obrist, F., Manic, G., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.974463 · Cited by 22
Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
Brierley, C. K., & Steensma, D. P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0344-z · Cited by 20
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
Phillips, T. J., Devata, S., & Wilcox, R. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0201-6 · Cited by 21
Recent Advances in Small Molecular Modulators Targeting Histone Deacetylase 6
Xiao, Y., & Zhang, X. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0023 · Cited by 20
Fürstenau, M., Fink, A. M., Schilhabel, A., Weiss, J. M., Robrecht, S., Eckert, R., de la Serna, J., Crespo, M., Coscia, M., Vitale, C., et al. (2020) · Blood · doi:10.1182/blood.2020008609 · Cited by 20
Targeted Therapies for Multiple Myeloma
Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 21
Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma
Talley, P., Chantry, A., & Buckle, C. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldu041 · Cited by 21
Chang, X., Qu, F., Li, C., Zhang, J., Zhang, Y., Xie, Y., Fan, Z., Bian, J., Wang, J., Li, Z., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22024 · Cited by 21
Song, Y., Zhang, Y., Wang, Z., Lin, Y., Cao, X., Han, X., Li, G., Hou, A., & Han, S. (2024) · Oncogene · doi:10.1038/s41388-024-03118-w · Cited by 18
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
Jin, Y., & Lee, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400267 · Cited by 21
Luo, Z., Lin, C., Yu, C., Yuan, C., Wu, W., Xu, X., Sun, R., Jia, Y., Wang, Y., Shen, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1093 · Cited by 19
Development of Potent and Selective CK1α Molecular Glue Degraders
Geng, Q., Jiang, Z., Byun, W. S., Donovan, K. A., Zhuang, Z., Jiang, F., Jones, H. M., Razumkov, H., Tang, M. T., Sarott, R. C., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02415 · Cited by 21
Chu, Y., Chen, S., Yang, M., Chen, Y., Fang, H., Huang, P., Xie, Y., Sun, C., Chen, Y., Zhang, B., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02793-8 · Cited by 19
Benchmarking Cofolding Methods for Molecular Glue Ternary Structure Prediction
Liao, Y., Zhu, J., Xie, J., Lai, L., & Pei, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01860 · Cited by 24
Salvage Therapy of Multiple Myeloma: The New Generation Drugs
Romano, A., Conticello, C., Cavalli, M. M., Vetro, C., Raimondo, C. D., Martina, V., Schinocca, E., Fauci, A. L., Parrinello, N. L., Chiarenza, A., et al. (2014) · BioMed Research International · doi:10.1155/2014/456037 · Cited by 19
Sawamura, N., Yamada, M., Fujiwara, M., Yamada, H., Hayashi, H., Takagi, N., & Asahi, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-20911-2 · Cited by 18
Franssen, L. E., Nijhof, I. S., Bjorklund, C. C., Chiu, H., Doorn, R., van Velzen, J. F., Emmelot, M. E., van Kessel, B., Levin, M., Bos, G. M. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26131 · Cited by 19
Bohl, S., Schmalbrock, L. K., Bauhuf, I., Meyer, T., Dolnik, A., Szyska, M., Blätte, T. J., Knödler, S., Röhner, L., Miller, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003541 · Cited by 19
Self-citationLv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Jin, Z., Xiang, R., Qing, K., Li, D., Liu, Z., Li, X., Zhu, H., Zhang, Y., Wang, L., Xue, K., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00833-6 · Cited by 19
Self-citationNovel insights into the mechanism of action of lenalidomide
Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 19
Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner
Zhou, L., Hao, Z., Wang, G., & Xu, G. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx433 · Cited by 19
Recent advances in target identification of bioactive natural products
Yoshida, M. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1533804 · Cited by 19
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Petrucci, M. T., Ricciardi, M. R., Molfetta, R., Paolini, R., Santoni, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1562-9 · Cited by 18
Hypnotic effect of thalidomide is independent of teratogenic ubiquitin/proteasome pathway
Hirose, Y., Kitazono, T., Sezaki, M., Abe, M., Sakimura, K., Funato, H., Handa, H., Vogt, K. E., & Yanagisawa, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917701117 · Cited by 19
Heim, C., Maiwald, S. A., Steinebach, C., Collins, M. K., Strope, J. D., Chau, C. H., Figg, W. D., Gütschow, M., & Hartmann, M. D. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.117 · Cited by 19
Heim, C., & Hartmann, M. D. (2022) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798322000092 · Cited by 20
Davis, L. N., Walker, Z. J., Reiman, L. T., Parzych, S. E., Stevens, B. M., Jordan, C. T., Forsberg, P. A., & Sherbenou, D. W. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0256 · Cited by 17
IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression
Hirsch, T., Neyens, D., Duhamel, C., Bayard, A., Vanhaver, C., Luyckx, M., de Oyanguren, F. S., Wildmann, C., Dauguet, N., Squifflet, J.-L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114401 · Cited by 20
Exploiting large-scale drug-protein interaction information for computational drug repurposing
Liu, R., Singh, N. P., Tawa, G. J., Wallqvist, A., & Jaques Reifman, A. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-210 · Cited by 18
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 18
Self-citationKalff, A., Khong, T. T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R. Z., Wang, M., Couto, S. S., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571201 · Cited by 19
Won, H.-R., Lee, D. H., Yeon, S.-K., Ryu, H., Kim, G. W., & Kwon, S. H. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4828 · Cited by 18
Nutt, M. J., & Stewart, S. G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104010 · Cited by 20
IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease
Liu, Q., Zheng, Y., Sturmlechner, I., Jain, A. K., Own, M., Yang, Q., Zhang, H., Vairo, F. P. E., Cerosaletti, K. M., Buckner, J. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178692 · Cited by 21
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 19
Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway
Mitsiades, C. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5748 · Cited by 18
Millrine, D., Tei, M., Gemechu, Y., & Kishimoto, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611751113 · Cited by 18
Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3
Liu, X., Li, H., Zhang, Q., Zeng, X., & Liu, S.-Q. (2018) · Medical Science Monitor · doi:10.12659/msm.907058 · Cited by 18
Tao, J., Yang, J., & Xu, G. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.058 · Cited by 19
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
Li, S., Vallet, S., Sacco, A., Roccaro, A. M., Lentzsch, S., & Podar, K. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1605354 · Cited by 18
Use of novel therapies in the treatment of light chain amyloidosis.
Varga, C., Titus, S. E., Toskic, D., & Comenzo, R. (2019) · Blood reviews · doi:10.1016/j.blre.2019.05.005 · Cited by 13
Li, S., Fu, J., Yang, J., Ma, H., Bhutani, D., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2020) · Blood · doi:10.1182/blood.2020006334 · Cited by 18
Murugesan, A., Lassalle-Claux, G., Hogan, L., Vaillancourt, E., Selka, A., Luiker, K., Kim, M. J., Touaibia, M., & Reiman, T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00350 · Cited by 18
Maffei, R., Fiorcari, S., Benatti, S., Atene, C. G., Martinelli, S., Zucchini, P., Potenza, L., Luppi, M., & Marasca, R. (2021) · Leukemia · doi:10.1038/s41375-021-01178-5 · Cited by 18
Perini, T., Materozzi, M., & Milan, E. (2021) · FEBS Journal · doi:10.1111/febs.16068 · Cited by 18
Metadata
- Authors
- Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 301-305
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4077049
- OpenAlex
- W2015345028
- Semantic Scholar
- bf4fc60d821257f664ef758f219b75586ad0adaa
- Cited by
- 1,879
- References
- 31
- Citations by year
- 2026: 159 · 2025: 188 · 2024: 185 · 2023: 169 · 2022: 176 · 2021: 196 · 2020: 186 · 2019: 138 · 2018: 125 · 2017: 100 · 2016: 102 · 2015: 88 · 2014: 59
- FWCI
- 37.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5p01ca078378-15)
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Human Genome Research Institute (RL1HG004671)
- National Cancer Institute (P01-CA078378, P50CA100707, P01CA108631, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, multiple myeloma, IKZF1, IKZF3, selective protein degradation, E3 ubiquitin ligase, ubiquitination, mechanism of action, IL-2 production, T cells, transcription factors
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Interleukin-2, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cell Line, Tumor, Ikaros Transcription Factor, Ubiquitination, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
